Labcorp (NYSE: LH) EVP awarded 6,100 options and 2,020 RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, received new equity awards. On February 10, 2026 he was granted 6,100 non-qualified stock options with an exercise price of $284.5 per share, vesting in three equal annual installments beginning February 10, 2027.

He was also granted 2,020 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments starting February 10, 2027. After this grant, he holds 6,100 options and 4,910 RSUs directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Caveney Brian J

Role EVP, Pres of ED, CMO & CSO

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	6,100	$0.00	--
Grant/Award	Restricted Stock Unit	2,020	$0.00	--

Holdings After Transaction: Non-qualified Stock Options — 6,100 shares (Direct); Restricted Stock Unit — 4,910 shares (Direct)

Footnotes (1)

Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The option vests in three equal annual installments beginning on the date reflected in this column. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

02/12/2026 - 03:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caveney Brian J

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Pres of ED, CMO & CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Options⁽¹⁾	$284.5	02/10/2026		A		6,100		02/10/2027⁽²⁾	02/09/2036	Common Stock	6,100	$0	6,100	D
Restricted Stock Unit	⁽³⁾	02/10/2026		A		2,020		⁽⁴⁾	⁽⁴⁾	Common Stock	2,020	$0	4,910⁽⁵⁾	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Brian J. Caveney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Labcorp (LH) executive Brian Caveney receive?

Brian Caveney received 6,100 non-qualified stock options and 2,020 Restricted Stock Units. The options have a $284.5 exercise price, and both awards vest in three equal annual installments, starting in 2027, aligning his compensation more closely with Labcorp’s long-term stock performance.

When do Brian Caveney’s new Labcorp (LH) stock options vest?

The 6,100 non-qualified stock options vest in three equal annual installments beginning on February 10, 2027. This means the options become exercisable gradually over three years, encouraging longer-term retention and performance alignment with Labcorp’s shareholders and strategic objectives.

What are the terms of Brian Caveney’s Restricted Stock Units at Labcorp (LH)?

Caveney was granted 2,020 Restricted Stock Units, each equal to one share of Labcorp common stock. These RSUs vest in three equal annual installments starting February 10, 2027, creating a multi-year incentive structure tied directly to the company’s share value over time.

How many Labcorp (LH) Restricted Stock Units does Brian Caveney hold after this grant?

After the February 10, 2026 grant, Brian Caveney holds a total of 4,910 Restricted Stock Units. This figure reflects the aggregate RSUs in his name, combining previously granted units with the new 2,020-unit award disclosed in this insider transaction report.

What is the exercise price on Brian Caveney’s new Labcorp (LH) stock options?

The newly granted 6,100 non-qualified stock options carry an exercise price of $284.5 per share. This is the fixed price at which he can buy Labcorp common stock once the options vest, linking potential value to future stock performance above that level.

Under which plan were Brian Caveney’s Labcorp (LH) options granted?

The employee stock options were granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. This plan governs equity-based compensation for eligible participants, using option and RSU awards to support retention and to align management incentives with shareholder interests.